近年来,得益于医药利好政策支持、高额研发投入,国内创新药企取得跨越式发展,出海已逐渐成为国内创新药企拓展盈利来源的全新渠道。值得一提的是,不少企业2025年实现净利润增长或减亏,就得益于新药放量与授权。如近期,百济神州发布2025年度业绩快报显示,报告期内,公司营收382.05亿元,同比上升40.4%。其中,产品收入为377.70亿元(上年同期产品收入为269.94亿元),同比上升39.9%。产品...
Source Link近年来,得益于医药利好政策支持、高额研发投入,国内创新药企取得跨越式发展,出海已逐渐成为国内创新药企拓展盈利来源的全新渠道。值得一提的是,不少企业2025年实现净利润增长或减亏,就得益于新药放量与授权。如近期,百济神州发布2025年度业绩快报显示,报告期内,公司营收382.05亿元,同比上升40.4%。其中,产品收入为377.70亿元(上年同期产品收入为269.94亿元),同比上升39.9%。产品...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.